Publications

What we publish
Unveiling Our Latest findings
  1. Gholizadeh, E., et al. (2024). Exploring Mechanisms of Action in Combinatorial Therapies through Solubility Alterations: Advancing AML Treatment. bioRxiv, 2024.11.08.618644. https://doi.org/10.1101/2024.11.08.618644
  2. Gholizadeh, E., et al. (2024). Targeting AML Resistance with LY3009120-Sapanisertib and Ruxolitinib-Ulixertinib Combinations Demonstrate Superior Efficacy in FLT3, TP53, and MUC4 mutations. bioRxiv, 2024.12.31.630711. https://doi.org/10.1101/2024.12.31.630711
  3. Zangene, E., et al. (2023). DORSSAA: Drug-target interactOmics Resource based on Stability/Solubility Alteration Assay. bioRxiv, 2023.12.29.573639. https://doi.org/10.1101/2023.12.29.573639
  4. Jafari, M., et al. (2022). NIMAA: an R/CRAN package to accomplish NomInal data Mining AnAlysis. bioRxiv, 2022.01.13.475835. https://doi.org/10.1101/2022.01.13.475835.
Selected publications
  1. Nickchi, P., et al. 2025. Monitoring Functional Posttranslational Modifications Using a Data-Driven Proteome Informatic Pipeline. Proteomics, e202400238.
  2. Mirzaie, M., et al. 2024. Designing patient-oriented combination therapies for acute myeloid leukemia based on efficacy/toxicity integration and bipartite network modeling. Oncogenesis 13(1):11.
  3. Jafari, M., et al. 2022. Bipartite Network Models to Design Combination Therapies in Acute Myeloid Leukaemia. Nature Communications 13 (1): 2128.
  4. Jafari, M., et al. 2021. Re-Evaluating Experimental Validation in the Big Data Era: A Conceptual Argument. Genome Biology 22 (1): 71.
  5. Gholizadeh, E., et al. 2021. Identification of Celecoxib-Targeted Proteins Using Label-Free Thermal Proteome Profiling on Rat Hippocampus. Molecular Pharmacology 99 (5): 308–18.
  6. Barneh, F., et al. 2019. Integrated Use of Bioinformatic Resources Reveals That Co-Targeting of Histone Deacetylases, IKBK and SRC Inhibits Epithelial-Mesenchymal Transition in Cancer. Briefings in Bioinformatics 20 (2): 717–31.
  7. Wang, Z., et al. 2016. Extraction and Analysis of Signatures from the Gene Expression Omnibus by the Crowd. Nature Communications 7 (1): 12846.